Get the Stockscreener App
20.56
3.56%
-0.76
Pre-market:
20.50
-0.06
-0.29%
Roivant Sciences Ltd stock is traded at $20.56, with a volume of 8.08M.
It is down -3.56% in the last 24 hours and up +26.84% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$21.32
Open:
$21.07
24h Volume:
8.08M
Relative Volume:
1.01
Market Cap:
$14.04B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
3.6389
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
-0.05%
1M Performance:
+26.84%
6M Performance:
+91.08%
1Y Performance:
+72.05%
1-Day Range:
$20.54
$21.23
1-Week Range:
$19.79
$21.35
52-Week Range:
$8.73
$21.35
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
20.56 | 14.83B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.99 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.97 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.73 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
368.36 | 41.77B | 4.98B | 69.59M | 525.67M | 0.5197 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Can Roivant Sciences Ltd. (87S) stock resist broad market declinesDip Buying & Fast Gain Stock Tips - newser.com
Is Roivant Sciences Ltd. (87S) stock a momentum leaderJuly 2025 Price Swings & Expert Curated Trade Setups - newser.com
Best data tools to analyze Roivant Sciences Ltd. stock2025 EndofYear Setup & Community Consensus Stock Picks - newser.com
How to forecast Roivant Sciences Ltd. trends using time series2025 Investor Takeaways & Long-Term Safe Investment Plans - newser.com
Real time breakdown of Roivant Sciences Ltd. stock performance2025 Price Targets & Community Consensus Picks - newser.com
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced (NASDAQ:ROIV) - Seeking Alpha
Can Roivant Sciences Ltd. rally from current levelsJobs Report & Daily Momentum Trading Reports - newser.com
Roivant Sciences (ROIV): Evaluating Valuation After Earnings, Pipeline Wins, and Legal Milestone - simplywall.st
Can Roivant Sciences Ltd. (87S) stock survive global slowdown2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - newser.com
Roivant Sciences Hits New 52-Week High of $20.77, Up 94.9% Year-to-Date - Markets Mojo
Citigroup Maintains Roivant Sciences (ROIV) Buy Recommendation - Nasdaq
Looking Into Roivant Sciences Ltd's Recent Short Interest - Benzinga
Roivant Sciences at Guggenheim Conference: Strategic Pipeline Focus - Investing.com India
Transcript : Roivant Sciences Ltd. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-11-2025 08 - MarketScreener
Roivant Sciences at Guggenheim Conference: Strategic Pipeline Focus By Investing.com - Investing.com Australia
Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2026 Earnings Call Transcript - Insider Monkey
Will Roivant Sciences Ltd. stock gain from government policies2025 Trade Ideas & Daily Profit Focused Stock Screening - newser.com
ROIV Crosses Above Average Analyst Target - Nasdaq
Leerink Partners raises Roivant Sciences stock price target to $29 on model extension - Investing.com Australia
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Roivant Sciences Reports Q2 2025 Financial Results - TipRanks
ROIV SEC FilingsRoivant Sciences 10-K, 10-Q, 8-K Forms - Stock Titan
Is Roivant Sciences Ltd. (87S) stock prepared for digital transition2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Will Roivant Sciences’ (ROIV) Slowing Revenue Growth Shape Its Long-Term Innovation Story? - Yahoo Finance
Roivant Sciences earnings beat by $0.15, revenue fell short of estimates - Investing.com South Africa
Roivant Sciences (ROIV) PT Raised to $26 at Citi - StreetInsider
Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... By GuruFocus - Investing.com Canada
Roivant Sciences Q2 2026 Earnings Call Transcript - MarketBeat
Roivant Sciences Ltd. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ROIV) 2025-11-10 - Seeking Alpha
Earnings call transcript: Roivant Sciences Q2 2026 beats EPS forecast - Investing.com
Earnings call transcript: Roivant Sciences Q2 2026 beats EPS forecast By Investing.com - Investing.com Australia
Roivant Sciences Ltd. (ROIV) Tops Q2 EPS by 15c - StreetInsider
Roivant Sciences' Fiscal Q2 Net Loss Narrows, Revenue Falls - MarketScreener
Roivant Sciences Ltd. SEC 10-Q Report - TradingView
[8-K] Roivant Sciences Ltd. Reports Material Event | ROIV SEC FilingForm 8-K - Stock Titan
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update - The Manila Times
Biopharma Roivant's Q2 income from operations misses - MarketScreener
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q2 Revenue $1.6M, vs. FactSet Est of $5.6M - MarketScreener
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q2 Net Loss $0.17 a Share, vs. FactSet Est of $0.33 Loss - MarketScreener
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q2 Revenue $1.6M, vs. FactSet Est of $5.6M - MarketScreener
Is Roivant Sciences Ltd. stock recession proofJuly 2025 Trends & Precise Trade Entry Recommendations - newser.com
Roivant Sciences Insider Sold Shares Worth $4,044,000, According to a Recent SEC Filing - MarketScreener
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):